People Background Check
Find People:

Andrew L Mellor, Age 70720 Carriage Hls Ct, Augusta, GA 30907

Get Report
Known as:
Andrew Lee Mellor Andrew H Mellor Andrew D Mellor Andy L Mellor Andrew H Newton
Related to:
Rebecca Mellor

Andrew Mellor Phones & Addresses

720 Carriage Hills Ct, Augusta, GA 30907 (706) 868-9161

1406 Woodhill Trl, Augusta, GA 30909 (706) 729-1488

Martinez, GA

2021 Autumn Chase, Augusta, GA 30907 (706) 868-9161

Education

Degree: Graduate or professional degree

Mentions for Andrew L Mellor

Andrew Mellor resumes & CV records

Resumes

Andrew Mellor Photo 40

Director, Immunotherapy Center At Georgia Health Sciences University

Position:
Director, Immunotherapy Center at Georgia Health Sciences University, Professor of Medicine at Georgia Health Sciences University
Location:
Augusta, Georgia
Industry:
Research
Work:
Georgia Health Sciences University since 2002
Director, Immunotherapy Center Georgia Health Sciences University since 1995
Professor of Medicine National Institute for Medical Research 1988 - 1995
Senior Scientist CRC Northwick Park Hosptial 1984 - 1987
Scientist Biogen 1982 - 1984
Research Scientist National Institute for Medical Research 1979 - 1982
Postdoctoral fellow
Education:
University of London 1976 - 1979
PhD, Tumour Virology University of Cambridge 1973 - 1976
BA (MA), Natural Sciences Tripos (Biochemistry)
Interests:
inflammation, immune tolerance, T cell immunobiology, immunotherapy to treat cancer, infectious/autoimmune diseases & transplant patients
Honor & Awards:
Bradley-Turner & Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics
Andrew Mellor Photo 41

Andrew Mellor

Andrew Mellor Photo 42

Andrew Mellor

Publications & IP owners

Us Patents

Regulation Of T Cell-Mediated Immunity By Tryptophan

US Patent:
6451840, Sep 17, 2002
Filed:
Dec 4, 1998
Appl. No.:
09/206274
Inventors:
David Munn - Augusta GA
Andrew Mellor - Augusta GA
Assignee:
Medical College of Georgia Research Institute, Inc. - Augusta GA
International Classification:
C07D40102
US Classification:
514419, 4242781
Abstract:
A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO. Similarly, increasing tryptophan degradation (thereby, decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. Although described particularly with reference to IDO regulation, one can instead manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer other tryptophan degrading enzymes.

Regulation Of T Cell-Mediated Immunity By Tryptophan

US Patent:
6482416, Nov 19, 2002
Filed:
Nov 30, 2000
Appl. No.:
09/727055
Inventors:
David Munn - Augusta GA
Andrew Mellor - Augusta GA
Assignee:
Medical College of Georgia Research Institute, Inc. - Augusta GA
International Classification:
A61K 4700
US Classification:
4242781, 514419
Abstract:
A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO. Similarly, increasing tryptophan degradation (thereby, decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. Although described particularly with reference to IDO regulation, one can instead manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer other tryptophan degrading enzymes.

Regulation Of T Cell-Mediated Immunity By Tryptophan

US Patent:
7160539, Jan 9, 2007
Filed:
Mar 28, 2002
Appl. No.:
10/112362
Inventors:
David Munn - Augusta GA, US
Andrew Mellor - Augusta GA, US
Assignee:
Medical College of Georgia - Augusta GA
International Classification:
A61K 48/00
C12N 5/00
C12N 15/63
US Classification:
424 9321, 424 932, 424 931, 4353201, 435325, 435455
Abstract:
A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO. Similarly, increasing tryptophan degradation (thereby , decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. Although described particularly with reference to IDO regulation, one can instead manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer other tryptophan degrading enzymes.

Chemokine Receptor Antagonists As Therapeutic Agents

US Patent:
7465448, Dec 16, 2008
Filed:
Sep 11, 2003
Appl. No.:
10/660131
Inventors:
David H. Munn - Augusta GA, US
Andrew L. Mellor - Martinez GA, US
Assignee:
Medical College of Georgia Research Institute, Inc. - Augusta GA
International Classification:
A61K 39/00
US Classification:
4241411, 4241431
Abstract:
The present invention provides methods and compositions to reduce immune tolerance at specific sites. In one aspect, the present invention comprises methods and compositions to reduce tumorigenicity. In an embodiment, the present invention reduces recruitment of tolerance-inducing antigen presenting cells (APCs) or their precursors to a tumor and/or tumor draining lymph node by decreasing binding of at least one tumor-associated ligand to a chemokine receptor present on the tolerance-inducing APCs or APC precursors. In an embodiment, the chemokine receptor is CCR6 and the tumor-associated ligand is mip-3α. In another aspect, the present invention comprises methods and compositions to reduce immune tolerance to a virus. In an embodiment, the virus is HIV. The present invention further provides for the development of CCR6 antibodies and antagonists as therapeutic agents to prevent or reduce immune tolerance.

Use Of Inhibitors Of Indoleamine-2,3-Dioxygenase In Combination With Other Therapeutic Modalities

US Patent:
7598287, Oct 6, 2009
Filed:
Feb 17, 2004
Appl. No.:
10/780797
Inventors:
David Munn - Augusta GA, US
Andrew Mellor - Augusta GA, US
Assignee:
Medical College of Georgia Research Institute, Inc. - Augusta GA
International Classification:
A61K 31/40
US Classification:
514419
Abstract:
The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

Kits To Assess The Risk Of Tumor Progression

US Patent:
7763251, Jul 27, 2010
Filed:
Jun 23, 2006
Appl. No.:
11/474144
Inventors:
Andrew L. Mellor - Augusta GA, US
David H. Munn - Augusta GA, US
Jeffrey Roberts Lee - Martinez GA, US
Assignee:
Medical College of Georgia Research Institute, Inc. - Augusta GA
International Classification:
A61K 39/395
C07K 16/00
US Classification:
4241531, 5303896
Abstract:
The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. Also disclosed are kits for assessing the relative risk of tumor progression in a subject. For example, disclosed are kits for assessing the relative risk of tumor progression in a subject and having reagents for detection of the enzyme indoleamine 2,3-dioxygenase (IDO) in a sample of tissue from a tumor or tumor draining lymph node from a subject, wherein the reagents are packaged in at least one individual container. The kits may include reagents for detection of cell surface or immunohistochemical markers associated with high IDO expression by APCs such as DO, CD123, CD11c or CCR6.

Regulation Of T Cell-Mediated Immunity By Tryptophan

US Patent:
7879791, Feb 1, 2011
Filed:
Nov 21, 2006
Appl. No.:
11/602930
Inventors:
David Munn - Augusta GA, US
Andrew Mellor - Augusta GA, US
Assignee:
Medical College of Georgia Research Institute, Inc. - Augusta GA
International Classification:
A61K 31/00
C07D 209/20
US Classification:
514 1, 548496
Abstract:
A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO. Similarly, increasing tryptophan degradation (thereby, decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. Although described particularly with reference to IDO regulation, one can instead manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer other tryptophan degrading enzymes.

Regulation Of T Cell-Mediated Immunity By Tryptophan

US Patent:
8198265, Jun 12, 2012
Filed:
Nov 21, 2006
Appl. No.:
11/603291
Inventors:
David Munn - Augusta GA, US
Andrew Mellor - Augusta GA, US
Assignee:
Medical College of Georgia Research Institute Inc. - Augusta GA
International Classification:
A61K 31/00
A61K 9/20
A61K 9/22
US Classification:
514183, 424451, 424457, 424463, 424464
Abstract:
A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO. Similarly, increasing tryptophan degradation (thereby, decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. Although described particularly with reference to IDO regulation, one can instead manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer other tryptophan degrading enzymes.

Possible Relatives

Donna L Mellor  Edward W Mellor  Frances K Mellor  Harold Mellor  Adam Mellor  Jackie E Mellor  James A Mellor  Andrew C Johnston  Andrew D Stanek  Andrew J Stanfill 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.